NCT03343665View on ClinicalTrials.gov

Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

December 20, 2019

Study Completion Date

December 20, 2019

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Nivolumab 40 mg in 4 ml Injection

40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days

Trial Locations (1)

197089

First Pavlov State Medical University of St. Petersburg, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER

NCT03343665 - Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma | Biotech Hunter | Biotech Hunter